MINC-trastuzumab (STM-001) / Suntec Medical - LARVOL DELTA

Correlation of Trop2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models (SABCS 2022) - "In vivo, 20% of ER+/Trop2+ models reported sensitivity to SG, most notably models from patients with acquired resistance to CDK4/6 inhibitors, including STM001 and ST4316B. We screened 180 models in our XPDX breast cancer platform for Trop2 expression and compared expression with in vivo SG efficacy in 125 models. Analysis is underway to correlate receptor and molecular profiles with SG sensitivity in breast models and we are expanding expression and in vivo testing to additional indications."

Preclinical • Breast Cancer • HER2 Breast Cancer • Oncology • Triple Negative Breast Cancer • ER • HER-2 • PGR • TACSTD2